7 results about "Infectious gastroenteritis" patented technology

The invention discloses a vaccine freeze-dried heat-resistant protective agent and a preparation method and application thereof. The freeze-dried heat-resistant protective agent consists of the following components in weight percentage: 0.6-1.0% of gelatin, 4.5-6.5% of brain heart infusion, 3.5-5.5% of tryptone, 6-10% of trehalose, 2.0-3.0% of sucrose, 1.5-2.5% of sodium thiosulfate, 0.6-1.2% of polyvinyl pyrrolidone (PVPK30), 0.4-0.6% of dextran, 0.3-0.5% of mannitol, 0.2-0.4% of glycine, 0.04-0.06% of sodium glutamate, 0.2-0.3% of L-arginine, and the balance is water for injection. The freeze-dried heat-resistant protective agent of the vaccine disclosed by the invention has components that interact with each other, thereby improving the temperature tolerance of porcine infectious gastroenteritis, porcine epidemic diarrhea and porcine rotavirus triple live vaccines during freeze-drying, reducing the loss of efficacy, and the virus loss rate before and after freeze-drying does not exceed 0.2 titers.

The invention belongs to the technical field of biology, and particularly relates to application of an L-type calcium channel inhibitor in resisting porcine intestinal coronavirus infection. The porcine intestinal coronavirus comprises any one or more of transmissible gastroenteritis virus, porcine epidemic diarrhea virus and porcine D-type coronavirus. The L-type calcium channel inhibitor is prepared from any one or more of verapamil, nicardipine and nimodipine. Research finds that the L-type calcium channel inhibitor such as verapamil can significantly inhibit porcine intestinal coronavirus infection and mainly plays a role within one hour when porcine intestinal coronavirus infection occurs, and it is indicated that the L-type calcium channel inhibitor mainly hinders the invasion process of viruses. The invention develops a brand new field for application of L-type calcium channel inhibitors such as verapamil, and also provides a new direction for research and development of novel anti-porcine intestinal coronavirus drugs.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating transmissible gastroenteritis (TGE) of lactating piglets, which effectively solves the problem that the prior art is only directed to the transmissible gastroenteritis with a low mortality rate of the piglets or sows with a mild disease, is not directed to the TGE with a high mortality rate of the lactating piglets with a severe disease, and cannot rapidly correct the problems of dehydration and acidosis of the lactating piglets, compared with the prior art, the traditional Chinese medicine composition for treating the TGE of the lactating piglets comprises Nansha-Shen, Beisha-Shen, Shihu, Yuzhu, Oyster, and can nourish Yin and produce body fluid, can effectively improve the dehydration and metabolic acidosis of the lactating piglets, and achieve the effects of treating the TGE and reducing the mortality rate, and the reasonable process is adopted to prepare the traditional Chinese medicine composition, so that the traditional Chinese medicine composition is convenient to use.

The invention discloses a nanoparticle antigen based on a ferritin vector, a recombinant expression vector, a recombinant lentiviral vector and a preparation method and application of the nanoparticle antigen. The nanoparticle antigen comprises recombinant protein formed by fusion of a swine transmissible gastroenteritis virus spike protein receptor binding domain and a ferritin subunit through a flexible connecting peptide, the recombinant protein is self-assembled to form the spherical nanoparticle antigen. According to the invention, eukaryotic expression plasmids and lentivirus packaging plasmids are successfully constructed, and efficient expression and purification of the fusion protein in HEK293T cells and ExpiCHO cells are realized. The purified recombinant protein can be spontaneously assembled in vitro to form spherical nanoparticles with uniform structure and regular form. Transmission electron microscope detection proves that the compound has good structural integrity and high-density multivalent antigen display capability. The vaccine has the advantages of high safety, strong immunogenicity, easiness in industrialization and the like, and a new technical path is provided for development of TGEV and related coronavirus vaccines.

The application provides a pig getah virus positive serum and a preparation method and application, and belongs to the technical field of animal virology. The application provides a preparation method of a pig getah virus positive serum, wherein a CDCD pig is used as a host, neutralizing antibody titer obtained through multiple immunization of high-concentration antigen is greater than or equal to 1:512; the serum does not have cytotoxicity affecting cell culture; the CDCD pig is a pig free from maternal antibody interference, which is obtained through caesarean section, isolated feeding and artificial feeding; the positive serum does not detect pig pseudorabies virus, swine fever virus, porcine circovirus type 2, pig foot-and-mouth disease virus, bovine viral diarrhea virus, porcine infectious gastroenteritis virus, porcine epidemic diarrhea virus, porcine rotavirus, porcine parvovirus, porcine Japanese encephalitis virus antibody, and has the characteristics of high titer and no cytotoxicity.

The invention belongs to the technical field of microorganisms, and particularly discloses bacillus amyloliquefaciens and application thereof. The bacillus amyloliquefaciens K1 has been preserved in the Guangdong Microbial Culture Collection Center on August 5, 2024, and the preservation number of the bacillus amyloliquefaciens K1 is GDMCC (China General Microbiological Culture Collection Center) NO: 64954, and the bacillus amyloliquefaciens K1 has been preserved in the Guangdong Microbial Culture Collection Center on August 5, 2024; fermentation supernate of the strain contains antibacterial substances, has a good effect of inhibiting clostridium perfringens and can be used for preparing products for inhibiting clostridium perfringens; besides, the generated surfactin can inhibit the replication of TGEV and PEDV viruses, so that the surfactin can be used for preparing medicines for treating or preventing porcine epidemic diarrhea and porcine infectious gastroenteritis, or other surfactin production products, and can effectively solve the problems in the current products.

This invention belongs to the field of veterinary biological agent technology, specifically relating to a bacterial-enzyme complex preparation for the prevention and treatment of transmissible gastroenteritis (TGEV) in pigs, its preparation method, and its application. The bacterial-enzyme complex preparation comprises microcapsule particles; the core material of each microcapsule particle includes a complex of probiotics and a synergistic enzyme system; the complex of probiotics includes *Lactobacillus rhamnosus*, *Bacillus coagulans*, *Pediococcus pentosus*, and *Kluyveromyces marsupialis*. In the bacterial-enzyme complex preparation for the prevention and treatment of TGEV provided by this invention, the complex probiotics and the synergistic enzyme system form a synergistic effect. Lactic acid secreted by *Lactobacillus rhamnosus* can lower the intestinal pH, disrupting the TGEV survival environment; antimicrobial peptides produced by *Bacillus coagulans* can directly cleave the viral capsid protein; lysozyme can degrade viral envelope polysaccharides; and neutral protease, β-glucanase, and xylanase can destroy the viral adsorption sites on the intestinal mucosa. This quadruple action significantly enhances the antiviral effect.